Last updated: August 17, 2026

Examiner: CHANDRA, GYAN

Tech Center 1600 • Art Units: 1646 1653 1674

This examiner grants 71% of resolved cases

Performance Statistics

71.3%

Allow Rate

+11.3% vs TC avg

1,028

Total Applications

+27.4%

Interview Lift

935

Avg Prosecution Days

Based on 1000 resolved cases, 2023–2026

4.1%

§101 Eligibility

15.0%

§102 Novelty

31.6%

§103 Obviousness

30.5%

§112 Clarity

App #	Title	Status	Assignee
18591754	CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS	Non-Final OA	Novo Nordisk A/S
18426412	GLP-1 RECEPTOR AGONISTS IN DEMENTIA	Non-Final OA	Novo Nordisk A/S
19415046	PEPTIDE ANALOGS AND METHODS OF USING THE SAME	Non-Final OA	Kallyope, Inc.
18409277	THERAPEUTIC USES OF DULAGLUTIDE	Non-Final OA	Eli Lilly and Company
18271173	ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS	Non-Final OA	THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.